Introduction
The precise definition of white coat hypertension (WCH) has been subject to much debate and discussion. As its name suggests, WCH originally referred to abnormally elevated blood pressure (BP) in the presence of a hospital or clinic doctor, who was usually wearing a white coat. This explanation requires some change nowadays as doctors often do not wear white coats and the abnormal elevation of BP occurs by the mere fact that the patient is attending 'someone', be it at a clinic or a hospital, to have his or her BP measured. The availability of ambulatory blood pressure monitoring (ABPM) devices, allowing measurement of the 24-h (or more) BP profile of the patient during everyday normal activity, has also influenced the concept and definitions of WCH.
Nevertheless, clinic BP has long been regarded as a surrogate marker of the 'true' BP in large population and other intervention studies, to which cardiovascular risk is related. This is reinforced by the finding that correction for regression dilution bias increases the strength of the association of cardiovascular risk and BP by approximately 60%. 1 Can the BP which is measured using a conventional mercury sphygmomanometer (using diastolic phase V and to the nearest 2 mm Hg, of course) after sitting in a quiet, darkened room after 10 min rest, truly reflect 'real' BP levels during daily activity? Although the concept of WCH is well-recognised, the clinical importance of isolated clinic hypertension is still much debated.
One possible definition of WCH has therefore been the presence of hypertension in the doctor's clinic with otherwise normal 24-h ambulatory BP recordings. The cynic would then argue that the presence of an ABPM monitor, with a cuff applied for 24 h and inflated every so often, is not really a true reflection of normality. This is also hampered by the lack of a precise definition of what ABPM Correspondence: Dr MJ Landray, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK normality constitutes. The definition of WCH is clearly dependent upon the definition of both clinic hypertension and on the definition of 'normal' ambulatory BP. However, in the absence of longterm prospective data on the relationship between ambulatory BP and cardiovascular risk, it is not possible to define 'normal' ambulatory BP. Most investigators have therefore attempted to determine such cut-offs from studies of the distribution of ambulatory BP in a 'normal' population. The selection of this 'normal' (sic) population is crucial to this calculation.
In a meta-analysis of 23 studies, using different recruitment criteria, and different measurement techniques (intra-arterial, auscultatory and oscillometric), Staessen et al 2 suggested hypertension was probably present if mean daytime BP using ABPM exceeded 146/91 mm Hg (based upon the mean plus 2 standard deviations). O'Brien et al 3 studied 815 healthy bank employees (who were not selected on the basis of their BP) and, using the 95th centile, were able to define age-and sex-specific cutoffs for daytime BP. These range from 131/83 mm Hg to 177/97 mm Hg, depending upon age and gender. Pickering et al 4 defined daytime hypertension as an ambulatory BP greater than 134/90 mm Hg, this being the 90th centile of the distribution in a normotensive population. However Verdecchia et al 5 defined normal ambulatory BP as less than 136/87 mm Hg in men, and 131/86 mm Hg in women, being the 90th centiles in a group of healthy normotensive volunteers. There is therefore little consistency between these definitions, and such an approach has a number of other inadequacies which are further discussed below.
Studies of the prevalence of WCH to date have usually used a clinic BP of greater than 140/90 mm Hg as the definition of clinical hypertension. As the definition of 'normal' ambulatory BP varies, this has a significant impact upon the proportion of patients who are identified as having WCH. For example, in a study by Verdecchia et al 5 of 285 patients with mild clinic hypertension (diastolic BP 90-104 mm Hg), the prevalence of WCH ranged from 14.7% to 59.6%, depending upon which criteria were used for ambulatory hypertension.
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Association with target organ damage
There have been conflicting reports about the association between WCH and abnormalities of cardiac structure and function. [5] [6] [7] [8] [9] [10] The lack of an agreed definition for WCH further adds to the confusion. Furthermore, interpretation of these studies has been made more difficult as many are not controlled for the level of ambulatory BP. It is therefore impossible to distinguish a dose-dependent response to BP level from a true WCH effect. 11, 12 For example, Verdecchia et al 5 studied left ventricular structure and function in 346 patients with clinic hypertension and showed a significant increase in left ventricular mass index (LVMI), and in the pattern of mitral blood flow (A/E ratio) in patients with established or persistent hypertension; this was regardless of whether they used their own definition or that of Staessen 2 or O'Brien. 3 The prevalence of echocardiographic left ventricular hypertrophy (LVH) in the patients with established hypertension ranged from 25% to 31% depending on the criteria used. When using their own criteria there was no detectable increase in LVMI or A/E ratio in WCH subjects, compared with normotensive controls. However, when using the Staessen or O'Brien criteria these measures of left ventricular structure and function were found to be significantly abnormal. Again, the prevalence of LVH ranged from 2.4% (not significantly different from normotensive controls) to 14.7% (P Ͻ 0.05), depending upon the definition used. 5 An alternative approach to this problem was taken by Hoegholm et al 13 who studied left ventricular structure in 420 patients with mild to moderate hypertension. Significant LVH was only present when the ambulatory daytime systolic BP was greater than 135 mm Hg, with no relationship with ambulatory daytime diastolic BP recordings. Using regression analysis amongst their normal controls, they found that a clinic BP recording of 140/90 mm Hg was equivalent to an ambulatory measurement of 135/90 mm Hg. At this level the LVMI and also the level of albuminuria were significantly lower when compared to patients with established hypertension, and was no different from normotensive controls. These data are nevertheless severely limited by their cross-sectional nature but perhaps should be regarded as the best indication of what we should consider as the threshold for ambulatory BP.
In a recent issue of the Journal of Human Hypertension, Owens et al 11 compare LVMI in patients with WCH and age-and sex-matched normotensive controls, where WCH was defined as a clinic BP greater than 140/90 mm Hg with a mean 24-h BP less than 135/70 mm Hg. They found that the LVMI was significantly greater in patients with WCH than in controls, a difference which persisted even after secondary matching for 24-h BP, and in a multiple regression model, WCH was the only significant predictor of LVMI. In contrast to Hoegholm et al, 13 14 demonstrated that patients with WCH had a significantly greater urinary albumin to creatinine ratio, suggesting an association with renal tubular injury. The level of microalbuminuria was nevertheless not as great as in those patients with established hypertension. WCH is also associated with changes in other cardiovascular risk factors, and in particular with the atherogenic lipid profile of hypertriglyceridaemia, hyperinsulinaemia and low levels of HDL-cholesterol. 15 Clearly WCH is unlikely to be a totally benign condition.
The evolution of WCH
It is important to distinguish whether WCH is a stable condition, perhaps associated with a mildly elevated risk of cardiovascular disease, or whether it represents a transition phase towards established, persistent hypertension.
In addressing this issue, it is helpful to examine the precursors of the WCH 'state'. For example, parents of individuals with WCH have been found to have raised levels of diastolic BP, whilst levels of mean childhood and young adulthood BPs are higher in patients with WCH than controls. 15 These features are therefore suggestive of a genetic or early environmental influence on BP. Individuals with WCH have also been shown to have increased levels of vascular resistance and resting heart rate, with values similar to those found in established hypertensive patients. In addition, there is some evidence of an increased re-absorption of sodium in the proximal tubule. 16 The possibility that WCH may perhaps be a transitional step on the road to 'true' hypertension has been reinforced by a study of 81 patients with untreated clinic hypertension, but normal ambulatory daytime BP recordings, where 60 (75%) of the patients developed established daytime hypertension after a mean follow-up for a mean of 5.7 years.
17
Clinical outcome
There are at present, no large prospective data on cardiovascular outcome in relation to ambulatory BP. Verdecchia et al 18 identified nearly 1200 patients with clinic hypertension, and 205 volunteers with normal BP recordings; on the basis of ABPM, these were divided into 205 normotensive controls, 228 patients with WCH, 693 patients with established hypertension and 266 patients with established hypertension without nocturnal dipping (non-dippers). Twenty-nine percent of the WCH group, and 56% of the established hypertension group received treatment during the follow-up period and follow-up was for a mean of 3.2 years (range 0.5-7.5). The overall cardiovascular event rate was low (2.0 per hundred patient years). The relative risk of such an event was not raised in the WCH population compared with controls, but significantly elevated in the dippers (relative risk 3.7, 95% confidence interval (CI) 1.13-12.50) and the non-dippers (relative risk 6.26, 95% CI 1.92-20.32). It should be noted however that the authors used their own definition of WCH (mean daytime BP less than 131/86 mm Hg in women or 136/87 mm Hg in men, with a clinic BP greater than 140/90 mm Hg), which was based upon the 90th centile of a healthy population. As detailed above, this definition of WCH was not actually associated with any significant changes in left ventricular structure or function in their previous cross-sectional study. 5 Therefore, this group of WCH patients might be considered as being at the mild end of the possible spectrum of WCH and established hypertension.
Treatment and WCH
At present there are no studies of the effects of antihypertensive treatment on the basis of ABPM recordings, either looking at regression of target organ damage or clinical end-points. This is in contrast to the large mass of data that convincingly demonstrates an overall 30% reduction in stroke and 16% reduction in coronary heart disease when antihypertensive treatment is instituted on the basis of clinic BP recordings. 19 Those familiar with the use of lipidlowering drugs for the prevention of cardiovascular disease will however be well aware of the fallacy of basing treatment decisions on cut-offs derived from the cholesterol distribution amongst the 'normal' population. Indeed, the risk of vascular disease can only be estimated on the basis of large-scale prospective data, taking into consideration the interactions with other well-known risk factors. In the absence of such information, treatment decisions should thus be made on the basis of repeated BP recordings.
Depending upon the definition used, approximately 20% of patients with clinic hypertension have normal levels of ambulatory BP at the time of screening. If these patients are left untreated, approximately 75% will develop established hypertension over the subsequent 5 years, so that at the end of this period only 5% of patients with clinic hypertension at baseline will not have established hypertension. 17 Given the possibility that WCH is associated with pathophysiological changes in haemodynamics and renal sodium handling, abnormal cardiovascular risk profile and target organ damage, and in the absence of clear clinical trial data to the contrary, one argument suggests that it seems most appropriate to treat on the basis of the clinic recording. The alternative strategy however is to repeat ABPM at frequent intervals. Nevertheless, WCH and established hypertension should perhaps be regarded as a continuum. Indeed previous attempts at cost analysis suggesting large cost savings by refusing drug treatment for those with WCH are probably flawed, as they do not consider the apparently high rate of evolution from WCH to established hypertension. 20 There is also no evidence that the benefits of antihypertensive drug treatment is simply confined to those with persistent hypertension.
Conclusion
WCH is a syndrome that clearly exists, but has no accepted definition and an undefined prognosis. It represents a condition for which the risks and benefits of treatment are unresearched. By contrast, the clinical and epidemiological importance of clinic BP and the definite, substantial benefits of its treatment are well documented. WCH should not therefore be simply dismissed as a benign entity that should be conveniently ignored. By contrast, patients with WCH should be carefully monitored although a policy of prescribing antihypertensive therapy in such patients is still uncertain. In the interim, the treatment of hypertension should perhaps be on the basis of careful clinic recordings until such time as there is clear prospective epidemiological data of the risks and benefits of ABPM readings and randomised controlled trials of antihypertensive treatment which are wholly based upon ABPM recordings.
